AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
AstraZeneca breast cancer pill faces review delay from regulators
FDA delays decision on AstraZeneca breast cancer pill
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…
